Methadone Treatment in Primary Care: Experience from Ontario, Canada 1980-2021
Webinar – Wednesday, May 31st @ 7pm ET Lori Regenstreif, MD Andrew McLeod Meldon Kahan, MD As the United States…
Webinar – Wednesday, May 31st @ 7pm ET Lori Regenstreif, MD Andrew McLeod Meldon Kahan, MD As the United States…
OASAS has posted the new OASAS Medical Advisory Panel (MAP) Xylazine Guidance document. Please share widely with your staff. Please…
April 26, 2023 by NYSAMGeneral
One year of pilot funding of up to $75,000 for research into chronic pain and opioid use disorder IMPOWR-ME is…
April 17, 2023 by NYSAMGeneral
Please join us for our upcoming General Membership Learning Session, scheduled for Monday, May 1st from 8-9PM. Pamela Mund, MD,…
March 30, 2023 by NYSAMMeetings
Join The Division on Addictions of the New York State Psychological Association (NYSPA) and the Concentration in Mental Health and…
On March 29th, the the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. This…